Primary Category:
Treatment Protocols
Disease Category:
Genitourinary
Status:
Temporarily Closed
A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
S1937 is temporarily closed to accrual, effective May 30, 2023 at 12:00pm PST.
Eligible for screening study DCP 001
NCT#04579224
